Status: Recruiting
Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors
The purpose of this research study is to evaluate the safety, tolerability and activity of VAX014 for intratumoral injections (VAX014) as a single agent as well as in combination with Investigator's choice of nivolumab or pembrolizumab in patients with advanced solid tumors. VAX014 is a targeted oncolytic agent designed to kill tumor cells following intratumoral injection into advanced solid tumors.
Participants needed: 48
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Vaxiion TherapeuticsUpdated: Aug 10, 2026Locations: 8
Eligibility criteria
Age 18+ [+23]
Injectable tumor not sufficiently distanced from critical structures (e.g., majo... [+16]